Single-arm open-label phase II study in children and adolescents of 177Lu-DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptor (SSTR) (LuPARPed).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512613-40-00

Acronym

LuPARPed-HM-2024

Enrollment

Registered

2024-08-02

Start date

2024-08-28

Completion date

Unknown

Last updated

2025-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent or relapsed solid tumours expressing somatostatin receptors

Brief summary

Primary endpoint of this study is objective tumour response. Tumour response is defined by RECIST v1.122 as complete response, partial response, stable response and progressive disease (for further details refer to the Appendix E or the publication22).

Interventions

DRUGLynparza 150 mg film-coated tablets

DRUGLutathera 370 MBq/mL solution for infusion

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Primary endpoint of this study is objective tumour response. Tumour response is defined by RECIST v1.122 as complete response, partial response, stable response and progressive disease (for further details refer to the Appendix E or the publication22).	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026